Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stomper, P. C.
Right arrow Articles by Kantoff, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stomper, P. C.
Right arrow Articles by Kantoff, P. W.

Radiology, Vol 180, 711-714, Copyright © 1991 by Radiological Society of North America

ARTICLES

CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?

PC Stomper, LA Kalish, MB Garnick, JP Richie and PW Kantoff
Department of Diagnostic Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.

Forty-eight patients with disseminated nonseminomatous germ cell tumors were studied retrospectively to determine whether initial pathologic features and pre- and post-chemotherapy computed tomographic (CT) features could be used to exclude malignancy or teratoma in residual masses that were excised after chemotherapy. Neither CT findings (residual mass size, attenuation, and degree of shrinkage during chemotherapy) nor type of primary testicular tumor cell was significantly correlated with malignancy or teratoma versus necrosis in residual masses. No significant correlation was demonstrated between the combined features of (a) the absence of teratoma in a histologic specimen of the primary testicular tumor and (b) greater than 90% shrinkage of masses during chemotherapy and the absence of malignancy or teratoma in residual masses as suggested in the literature. Of nine patients with both of these findings, two had malignancy and two had teratoma. Radiographic and pathologic features cannot be used to reliably exclude malignancy or teratoma in residual abdominal masses after chemotherapy for nonseminomatous testicular cancer.


This article has been cited by other articles:


Home page
 JCOHome page
K. Oechsle, M. Hartmann, W. Brenner, S. Venz, L. Weissbach, C. Franzius, S. Kliesch, S. Mueller, S. Krege, R. Heicappell, et al.
[18F]Fluorodeoxyglucose Positron Emission Tomography in Nonseminomatous Germ Cell Tumors After Chemotherapy: The German Multicenter Positron Emission Tomography Study Group
J. Clin. Oncol., December 20, 2008; 26(36): 5930 - 5935.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
P. J. Woodward, R. Sohaey, M. J. O'Donoghue, and D. E. Green
From the Archives of the AFIP: Tumors and Tumorlike Lesions of the Testis: Radiologic-Pathologic Correlation
RadioGraphics, January 1, 2002; 22(1): 189 - 216.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. W. Steyerberg, H. J. Keizer, D. T. Sleijfer, S. D. Fosså, D. F. Bajorin, A. Gerl, R. de Wit, W. J. Kirkels, H. S. Koops, and J. D. F. Habbema
Retroperitoneal Metastases in Testicular Cancer: Role of CT Measurements of Residual Masses in Decision Making for Resection after Chemotherapy
Radiology, May 1, 2000; 215(2): 437 - 444.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1991 by the Radiological Society of North America.